Inhibikase (IKT): יחס חוב כולל להון עצמי

The market price confirmed by the chart demonstrates that Inhibikase Therapeutics (IKT) has a total debt-to-equity ratio of 0.00. Inhibikase Therapeutics is developing an environment to combat dementia, where high volunteer engagement is combined with strict FDA oversight. The business relies on the creation of unique c-Abl inhibitors to slow neuronal degeneration. Distinguished scientists with access to substantial grants and creative independence are implementing these projects.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to the company's own equity. The dynamics of equity leverage allow for an assessment of financial stability and bankruptcy risks. High values signal a dependence on creditors, while low values indicate conservative management. For Inhibikase Therapeutics (IKT), the balance of liabilities is critical when financing long-term neurobiological research, which ensures the stability of joint developments for Parkinson's disease drugs.